COVID-19 PANDEMİSİNDE NEFROLOJİ KLİNİKLERİNİN YÖNETİMİ

Year 2020, Volume: 8 Issue: 3, 570 - 578, 20.12.2020

Nergiz Bayrakçı , Gülsüm Özkan

https://doi.org/10.37696/nkmj.771790

Abstract

ÖZ
SARS-COV2’nin etkeni olduğu COVİD-19 ciddi mortaliteye sebep olan, Dünya Sağlık Örgütü tarafından kısa süre içinde pandemi olarak ilan edilen bir hastalık halini almıştır. Semptomatik olguların büyük kısmında hastalık hafif semptomlarla geçirilse de bazı hastaların mortalite ve morbidite açısından daha yüksek risk grubunda oldukları görülmüştür. Hipertansiyon başta olmak üzere kronik kardiyovasküler hastalığı olan hastalar ve glomerülonefritler, renal tranplantasyon ve diğer sebeplere bağlı kronik böbrek hastalıklarını içeren kronik renal hastalığı olanlar bahsi geçen yüksek risk grubundadır. Öte yandan böbrekler COVİD-19 seyrinde akut biçimde de en sık ve ağır biçimde etkilenen organlar arasında yer almaktadır. Hastalığın kesin bir tedavisinin olmaması, etkilenen organlarda uzun vadedeki etkilerinin bilinmemesi nedeniyle koruyucu önlemler COVİD-19 pandemisinin yönetiminde kilit role sahiptir. Tüm bu özelliklerinden ötürü COVİD-19 pandemisi nefroloji kliniklerinde özel koruyucu önlemler alınmasını, tedavi ve takipte kısa ve uzun vadeli planlamalar yapılmasını gerekli kılmıştır. Bu makalede COVİD-19 pandemisinde nefroloji kliniklerinde yapılması gereken düzenlemeler ve özel hasta gruplarının takibi özetlenecektir.
ABSTRACT
COVID-19, caused by SARS-COV2, has became a disease which is declared as a pandemic by World Health Organization in a short time. Although most symptomatic cases, result in minör symptoms; some patients were found to be at higher risk for mortality and morbidity. Patients with chronic cardiovascular morbidities, especially hypertension, and chronic renal morbidities including glomerulonephritis, renal transplantation and chronic kidney diseases due to other causes are included in the high-risk group. However, kidneys are among the most frequently and severely affected organs acutely in the course of the COVID-19. Preventive measures play a key role in COVID-19 pandemic management, as there is no definitive treatment for the disease and the long-term effects in involved organs are unknown. This has made it necessary to take special protective measures in nephrology clinics and to make short and long-term plans in treatment and follow-up. In this article, the arrangements to be made in nephrology clinics in COVID-19 pandemic and the follow-up of special patient groups will be summarized.

Keywords

COVİD-19, Hipertansiyon, Akut böbrek hasarı, Kronik böbrek hastalığı, Hemodiyaliz

References

• 1- Rothan HA, Byrareddy SN. The epidemiology and pathogenesis of coronavirus disease (COVID-19) outbreak. J Autoimmun. 2020;109:102433.
• 2- Du Toit A. Outbreak of a novel coronavirus. Nat. Rev. Microbiol. 2020;18(3):123.
• 3- Huang C., Wang Y., Li X., Ren L., Zhao J., Hu Y. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet. 2020;395(10223):497–506.
• 4- Ren L.L., Wang Y.M., Wu Z.Q., Xiang Z.C., Guo L., Xu T. Identification of a novel coronavirus causing severe pneumonia in human: a descriptive study. Chinese Med J. 2020;133(9):1015-1024.
• 5- Carlos W.G., Dela Cruz C.S., Cao B., Pasnick S., Jamil S. Novel wuhan (2019-nCoV) coronavirus. Am. J. Respir. Crit. Care Med. 2020;201(4):7-8.
• 6- Puelles VG, Lütgehetmann M, Lindenmeyer MT, Sperhake JP, Wong MN, Allweiss L, et al. Multiorgan and Renal Tropism of SARS-CoV-2. N Engl J Med. 2020; online ahead of print.
• 7- Pranata R, Lim MA, Huang I, Raharjo SB, Lukito AA. Hypertension is associated with increased mortality and severity of disease in COVID-19 pneumonia: A systematic review, meta-analysis and meta-regression. Version 2. J Renin Angiotensin Aldosterone Syst. 2020;21(2):1470320320926899.
• 8- Fang L, Karakiulakis G, Roth M. Are patients with hypertension and diabetes mellitus at increased risk for COVID-19 infection? Lancet Respir Med. 2020 Apr;8(4):e21.
• 9- Yang G, Tan Z, Zhou L, Yang M, Peng L, Liu J, et al. Effects of Angiotensin II Receptor Blockers and ACE (Angiotensin-Converting Enzyme) Inhibitors on Virus Infection, Inflammatory Status, and Clinical Outcomes in Patients With COVID-19 and Hypertension: A Single-Center Retrospective Study. Hypertension. 2020;76(1):51-58.
• 10- Rossi GP, Sanga V, Barton M. Potential harmful effects of discontinuing ACE-inhibitors and ARBs in COVID-19 patients. Elife. 2020;9:e57278. 11- Reynolds HR, Adhikari S, Pulgarin C, Troxel AB, Iturrate E, Johnson SB, et al. Renin-Angiotensin-Aldosterone System Inhibitors and Risk of Covid-19. N Engl J Med. 2020 Jun 18;382(25):2441-2448.
• 12- Statement by the ESC: https://www.escardio.org/Councils/Council-on-Hypertension-(CHT)/News/position-statement-of-the-esc-council-on-hypertension-on-ace-inhibitors-and-ang.
• 13- Cheng Y, Luo R, Wang K, Zhang M, Wang Z, Dong L, et al. Kidney disease is associated with in-hospital death of patients with COVID-19. Kidney Int. 2020;97(5):829-838.
• 14- Yang X, Yu Y, Xu J, Shu H, Xia J, Liu H, et al. Clinical course and outcomes of critically ill patients with SARS-CoV-2 pneumonia in Wuhan, China: a single-centered, retrospective, observational study. Lancet Respir Med. 2020;8(5):475-481.
• 15- Su H, Yang M, Wan C, Yi LX, Tang F, Zhu HY, et al. Renal histopathological analysis of 26 postmortem findings of patients with COVID-19 in China. Kidney Int. 2020;98(1):219-227.
• 16- Martinez-Rojas MA, Vega-Vega O, Bobadilla NA. Is the kidney a target of SARS-CoV-2? Am J Physiol Renal Physiol. 2020;318(6):F1454-F1462.
• 17- Ma Y, Diao B, Lv X, Zuhu J, Liang W, Liu L. et al. COVID-19 in hemodialysis (HD) patients: Report from one HD center in Wuhan, China. https://www.medrxiv.org/content/10.1101/2020.02.24.20027201v2.
• 18- Basile C, Combe C, Pizzarelli F, Covic A, Davenport A, Kanbay M, et al. Recommendations for the prevention, mitigation and containment of the emerging SARS-CoV-2 (COVID-19) pandemic in haemodialysis centres. Nephrol Dial Transplant. 2020;35(5):737-741.
• 19- Information for transplant professionals and community members regarding 2019 novel coronavirus. American Society for Transplantation. https://www.myast.org/sites/default/files/1COVID19%20FAQ%20Tx%20Centers%2004.15.2020.pdf (Accessed on April 18, 2020).
• 20- Türk Nefroloji Derneği. COVID-19 enfeksiyonu ve böbrek transplantasyonu. http://www.nefroloji.org.tr/haber.php?%20id=283
• 21- American Society of Transplant Surgeons. Re-engaging organ transplantation in the COVID-19 era. https://asts.org/advocacy/covid-19-resources/asts-covid-19-strike-force/re-engaging-organ-transplantation-in-the-covid-19-era#.XxNcSZ4zY2w. (Accessed on June 05.2020).
• 22- Loupy A , Aubert O , Reese P, Bastien O , Bayer F, Jacquelinet C. Organ procurement and transplantation during the COVID-19 pandemic. Lancet 2020;395(10237):e95-e96.
• 23- Pereira M, Mohan S, Cohen D, Husain S, Dube G, Ratner L et al. COVID-19 in solid organ transplant recipients: Initial report from the US epicenter. Am J Transplant 2020;20(7):1800-1808.
• 24- Aziz F, Jorgenson M, Garg N, Mohamed M, Djamali A, Mandelbrot D et al. The care of kidney transplant recipients during a global pandemic: Challenges and strategies for success. Transplantation Reviews Available online 12 July 2020, 100567
• 25- Türk Nefroloji Derneği Transplantasyon Çalışma Grubu. Renal transplantasyonlu hastalarda Covid-19 infeksiyonu izlem ve tedavi önerileri. http://www.nefroloji.org.tr/folders/file/TND-RTCG-Renal_Transplantasyonlu_Hastalarda_Covid-19_Infeksiyonu.pdf
• 26- Maggiore U, Abramowicz D, Crespo M, Mariat C, Mjoen G, Peruzzi L . How should I manage immunosuppression in a kidney transplant patient with COVID-19? An ERA-EDTA DESCARTES expert opinion. Nephrol Dial Transplant. 2020 Jun 1;35(6):899-904.
• 27- Alberici F, Delbarba E, Manenti C, Econimo L, Valerio F, Pola A et al. Management of Patients on Dialysis and With Kidney Transplantation During the SARS-CoV-2 (COVID-19) Pandemic in Brescia, Italy. Kidney Int Rep 2020;5:580–585.
• 28- Anders HJ, Bruchfeld A, Juarez G, Floege J, Goumenos D, Turkmen K et al. Recommendations for the management of patients with immune-mediated kidney disease during the severe acute respiratory syndrome coronavirus 2 pandemic. Nephrol Dial Transplant 2020;35(6):920-925.
• 29- Bomback A, Canetta P, Ahn W, Ahmad S, Radhakrishnan J, Appel G. How COVID-19 Has Changed the Management of Glomerular Diseases. Clin J Am Soc Nephrol.2020;15(6):876-879.
• 30- Türk Nefroloji Derneği Glomerüler Hastalıklar Çalışma Grubu. İmmunosupressif ilaç kullanılanan glomeruler hastalıklar için korona virüs salgını önerileri. http://www.nefroloji.org.tr/haber.php?%20id=283.
• 31- Fang X, Li S, Yu H, Wang P, Zhang Y, Chen Z et al. Epidemiological, comorbidity factors with severity and prognosis of COVID-19: a systematic review and meta-analysis. Aging (Albany NY). 2020 Jul;12.
• 32- Henry B, Lippi G, Chronic kidney disease is associated with severe coronavirus disease 2019 (COVID-19) infection. International Urology and Nephrology. 2020 ;52:1193–1194.